Biogen Stock Outlook: Is Wall Street Bullish or Bearish?
Biogen's Performance: Biogen Inc. has seen a significant decline in its stock, down 36.4% over the past year, underperforming compared to the S&P 500 Index and the iShares Neuroscience and Healthcare ETF, despite reporting a 3% revenue increase in Q4 that surpassed analyst expectations.
Analyst Ratings and Outlook: The consensus among analysts is a "Moderate Buy" for Biogen, with a lowered price target of $135 from Piper Sandler, while the mean price target suggests a potential upside of 41.4%, indicating cautious optimism amid a conservative earnings forecast for 2025.
Trade with 70% Backtested Accuracy
Analyst Views on IBRN
No data
About the author
Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland
Biohaven's Investment Agreement: Biohaven Ltd. has entered a $600 million investment agreement with Oberland Capital Management, structured through a non-dilutive Note Purchase Agreement, which will support clinical trials and commercialization of its drug, troriluzole, pending FDA approval.
Stock Performance: Following the announcement, Biohaven shares rose by 5.85% in premarket trading, reflecting positive investor sentiment regarding the funding and potential future developments related to the treatment for spinocerebellar ataxia.
Biogen Stock Outlook: Is Wall Street Bullish or Bearish?
Biogen's Performance: Biogen Inc. has seen a significant decline in its stock, down 36.4% over the past year, underperforming compared to the S&P 500 Index and the iShares Neuroscience and Healthcare ETF, despite reporting a 3% revenue increase in Q4 that surpassed analyst expectations.
Analyst Ratings and Outlook: The consensus among analysts is a "Moderate Buy" for Biogen, with a lowered price target of $135 from Piper Sandler, while the mean price target suggests a potential upside of 41.4%, indicating cautious optimism amid a conservative earnings forecast for 2025.
NVR Stock: Analyst Estimates & Ratings
NVR, Inc. Performance: NVR, Inc., a homebuilder with a market cap of $28.3 billion, has outperformed the S&P 500 and iShares U.S. Home Construction ETF over the past year, with shares up 51.2% compared to the S&P's 32.6% gain. Despite a recent earnings miss in Q3, revenue exceeded expectations.
Analyst Ratings and Price Targets: The consensus rating for NVR is a "Hold" among analysts, with UBS raising its price target from $8,450 to $9,450 while maintaining a "Neutral" rating. The mean price target suggests a potential upside of 1.7%, with a street-high target indicating a 6.3% upside from current levels.
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Company Performance: Biogen Inc. has significantly underperformed the market, with a 31.7% decline over the past year compared to a nearly 31% rise in the S&P 500; its recent Q3 results showed a 6.4% drop in adjusted EPS and a 2.5% decrease in revenue year-over-year.
Analyst Ratings and Future Outlook: Despite a mixed earnings surprise history, analysts maintain a "Moderate Buy" consensus on BIIB stock, with price targets suggesting potential upside ranging from 31.1% to 116.6% from current levels.
Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland
Biohaven's Investment Agreement: Biohaven Ltd. has entered a $600 million investment agreement with Oberland Capital Management, structured through a non-dilutive Note Purchase Agreement, which will support clinical trials and commercialization of its drug, troriluzole, pending FDA approval.
Stock Performance: Following the announcement, Biohaven shares rose by 5.85% in premarket trading, reflecting positive investor sentiment regarding the funding and potential future developments related to the treatment for spinocerebellar ataxia.
Biogen Stock Outlook: Is Wall Street Bullish or Bearish?
Biogen's Performance: Biogen Inc. has seen a significant decline in its stock, down 36.4% over the past year, underperforming compared to the S&P 500 Index and the iShares Neuroscience and Healthcare ETF, despite reporting a 3% revenue increase in Q4 that surpassed analyst expectations.
Analyst Ratings and Outlook: The consensus among analysts is a "Moderate Buy" for Biogen, with a lowered price target of $135 from Piper Sandler, while the mean price target suggests a potential upside of 41.4%, indicating cautious optimism amid a conservative earnings forecast for 2025.
NVR Stock: Analyst Estimates & Ratings
NVR, Inc. Performance: NVR, Inc., a homebuilder with a market cap of $28.3 billion, has outperformed the S&P 500 and iShares U.S. Home Construction ETF over the past year, with shares up 51.2% compared to the S&P's 32.6% gain. Despite a recent earnings miss in Q3, revenue exceeded expectations.
Analyst Ratings and Price Targets: The consensus rating for NVR is a "Hold" among analysts, with UBS raising its price target from $8,450 to $9,450 while maintaining a "Neutral" rating. The mean price target suggests a potential upside of 1.7%, with a street-high target indicating a 6.3% upside from current levels.
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Company Performance: Biogen Inc. has significantly underperformed the market, with a 31.7% decline over the past year compared to a nearly 31% rise in the S&P 500; its recent Q3 results showed a 6.4% drop in adjusted EPS and a 2.5% decrease in revenue year-over-year.
Analyst Ratings and Future Outlook: Despite a mixed earnings surprise history, analysts maintain a "Moderate Buy" consensus on BIIB stock, with price targets suggesting potential upside ranging from 31.1% to 116.6% from current levels.
